Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 17/20 | 0.78 |
| ▸ | MMP8 | P22894 | 5/20 | 0.78 |
| ▸ | ADAMTS4 | O75173 | 2/20 | 0.78 |
| ▸ | MMP13 | P45452 | 1/20 | 0.78 |
| ▸ | MMP2 | P08253 | 17/20 | 0.67 |
| ▸ | MMP12 | P39900 | 4/20 | 0.67 |
| ▸ | MMP14 | P50281 | 4/20 | 0.67 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL716323 | 0.89 | MMP9 (0.86) | MMP9MMP8ADAMTS4MMP13MMP2 | |
| SCHEMBL698930 | 0.89 | MMP9 (0.86) | MMP9MMP8ADAMTS4MMP13MMP2 | |
| SCHEMBL698929 | 0.89 | MMP9 (0.86) | MMP9MMP8ADAMTS4MMP13MMP2 | |
| SCHEMBL14602271 | 0.87 | MMP9 (1.00) | MMP9MMP8ADAMTS4MMP13MMP2 | |
| SCHEMBL31609930 | 0.87 | MMP9 (1.00) | MMP9MMP8ADAMTS4MMP13MMP2 | |
| SCHEMBL14602275 | 0.87 | MMP9 (1.00) | MMP9MMP8ADAMTS4MMP13MMP2 | |
| SCHEMBL28223016 | 0.85 | MMP9 (0.71) | MMP9MMP8ADAMTS4MMP13MMP2 | |
| SCHEMBL14748035 | 0.85 | MMP9 (0.71) | MMP9MMP8ADAMTS4MMP13MMP2 | |
| SCHEMBL28860664 | 0.85 | MMP9 (0.71) | MMP9MMP8ADAMTS4MMP13MMP2 | |
| SCHEMBL27387379 | 0.85 | MMP9 (0.71) | MMP9MMP8ADAMTS4MMP13MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6277880-B1 | ANTIBODY DIRECTED ENZYME PRODUG THERAPY | ZENECA LIMITED (GB) | 2001-08-21 | — | — | US | disclosed |
| US-5958971-A | PRODRUGS OF NITROGEN MUSTARD, AN ANTICARCINOGENIC AND TUMOR AGENT; ANTIBODY DIRECTED ENZYME PRODRUG THERAPY (ADEPT); BIOCHEMICAL CONJUGATION | ZENECA LIMITED (GB) | 1999-09-28 | — | — | US | disclosed |
| US-5714148-A | PRODRUGS WHICH ARE SUBSTRATES FOR CARBOXYPEPTIDASE G2 AND YIELD ACTIVE CYTOTOXIC DRUGS | ZENECA LIMITED (GB) | 1998-02-03 | — | — | US | disclosed |
| US-5660829-A | DEESTERIFYING COMPOUND TO FORM N-(4(N,N-BIS(2-CHLOROETHYL) AMINO)PHENOXYCARBONYL)-L-GLUTAMIC ACID-GAMMA-(3,5-DICARBOXY)ANILIDE | ZENECA LIMITED (GB) | 1997-08-26 | — | — | US | disclosed |
| US-5587161-A | TWO COMPONENT SYSTEM INCLUDING ANTIBODY OR ANTIGEN BINDING FRAGMENT CONJUGATED TO CARBOXYPEPTIDASE G ENZYME, COMPOUND CONVERTIBLE TO CYTOTOXIC DRUG UNDER INFLUENCE OF ENZYME | ZENECA LIMITED (GB) | 1996-12-24 | — | — | US | disclosed |
| EP-0651740-A1 | AMINO ACID LINKED NITROGEN MUSTARD DERIVATIVES AND THEIR USE AS PRODRUGS IN THE TREATMENT OF TUMOURS | ZENECA LIMITED (GB) | 1995-05-10 | — | — | EP | disclosed |
| US-5405990-A | For use in antibody directed enzyme prodrug therapy; cytotoxic parent nitrogen mustard; antitumor agents | ZENECA LIMITED (GB) | 1995-04-11 | — | — | US | disclosed |
| WO-1994002450-A1 | AMINO ACID LINKED NITROGEN MUSTARD DERIVATIVES AND THEIR USE AS PRODRUGS IN THE TREATMENT OF TUMOURS | ZENECA LIMITED (GB) | 1994-02-03 | — | — | WO | disclosed |